http://www.fpnotebook.com/
BusparAka: Buspirone
- Mechanism
- Azaperone modulates Serotonin transmission
- Dosing
- Start: 7.5 mg PO bid (or 5 mg PO tid)
- Effective dose: 20 to 30 mg per day
- Maximum: 60 mg per day
- Indications
- Anxiety Disorders
- Generalized Anxiety Disorder
- Chronic Anxiety Disorder
- Anxiety in the elderly
- Aggression in developmentally disabled
- Agitated Dementia
- Emotional behavioral problems in brain injury
- Geriatric Depression
- Adjunctive use with SSRI in Major Depression
- Mixed anxiety and depression
- Enhance Major Depression response to SSRI
- Antidepressant Induced Sexual Dysfunction
- Alcohol Withdrawal
- Reduces anxiety of "needing" a drink
- Obsessive Compulsive depression
- Use Buspar with Prozac
- Decreases Neuroleptic adverse effects
- Reduces Tardive Dyskinesia
- Reduces Akathisia
- Reduces Parkinsonism
- Anxiety Disorders
- Advantages compared with Benzodiazepines
- Non-addictive
- Less Sedation
- No associated memory Impairment
- No significant withdrawal syndrome
- Minimal overdose potential
- No Anticholinergic Toxicity
- Well tolerated by elderly patients
- Disadvantages compared with Benzodiazepine
- Slow onset of action (takes 2-4 weeks until effect)
- Not useful in Panic Attacks
- No sedative effect
- Requires repeat dosing 2-3 times per day
- Precautions
- Avoid use in pregnancy and Lactation
- Avoid in hepatic or renal Impairment
- Adverse Effects
- Drug Interactions
- MAO inhibitors
- Haloperidol (Haldol)
- Cyclosporine (Sandimmune)
- Disulfiram (Antabuse)
- Erythromycin and Itraconazole suppresses p450
- Results in Buspirone levels 5-13 times normal
- Protocol to convert from Benzodiazepine to Buspirone
- Convert short-acting Benzodiazepine to long-acting
- Example: Alprazolam to Clonazepam
- Start Buspirone at above doses
- Taper long-acting Benzodiazepine over 60 to 90 days
- Convert short-acting Benzodiazepine to long-acting
- References
Buspirone (C0006462) | |
|---|---|
| Definition (MSH) | An anxiolytic agent and a serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the benzodiazepines, but it has an efficacy comparable to DIAZEPAM. |
| Definition (CSP) | 8-(4-(2-pyrimidinyl)-1-piperazinyl) butyl-8-azaspirodecane-7,9- dione; serotonergic tranquilizer frequently contrasted with benzodiazepine-type, GABAergic tranquilizers. |
| Definition (NCI) | An anxiolytic agent chemically and pharmacologically unrelated to benzodiazepines, barbiturates, or other sedative/hypnotic drugs. Although its exact mechanism of action is unknown, buspirone may exert its anti-anxiety effects via serotonin (5-HT1A) and dopamine receptors (D2) and may indirectly affect other neurotransmitter systems. Unlike typical benzodiazepine anxiolytics, this agent does not exert anticonvulsant or muscle relaxant effects and lacks prominent sedative effects. |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D002065 |
| English | Buspirone, BUSPIRONE PREPARATION |
| Spanish | buspirona |
| Parent Concepts | Pyrimidines (C0034289), Tranquilizing Agents (C0040614), spirane (C0597504), Spiro Compounds (C0037968), Anti-Anxiety Agents (C0040616), [CN309] SEDATIVES/HYPNOTICS, OTHER (C0993165), Sedatives (C0036557), Drug allergen (C1320237), Anxiolytics, Other (C1579425) |
| Sources | AOD, CSP, LNC, MSH, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Buspar (C0600122) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D002065 |
| English | Bespar, Bristol Myers Brand of Buspirone Hydrochloride, Bristol Myers Squibb Brand of Buspirone Hydrochloride, Bristol-Myers Brand of Buspirone Hydrochloride, Bristol-Myers Squibb Brand of Buspirone Hydrochloride, Buspar, Hormosan Brand of Buspirone Hydrochloride, UPSA Brand of Buspirone Hydrochloride |
| Sources | MSH, MTH, PDQ, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |